Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial

Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial

Background In patients with untreated CD20-positive diffuse large B-cell lymphoma (DLBCL), a phase 3 trial was carried out to evaluate the efficacy and safety of zuberitamab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; Hi-CHOP) versus rituximab plus CHOP (R-CHOP) treatment...

Full description

Saved in:
Bibliographic Details
Main Authors: Hui Zhou, Jun Zhu, Yu Yang, Wei Yang, Liling Zhang, Lihong Liu, Mingzhi Zhang, Chuan He, Mei Zhang, Sujun Gao, Zhiming Li, Min Zhou, Hongmei Jing, Qingyuan Zhang, Ying Cheng, Yuqin Song, Zhengzi Qian, Xiuhua Sun, Wenyu Li, Haiyan Yang, Feng Yan, Ying Xiang, Bing Xu, Weihua Zhang, Xiaohong Zhang, Jie Jin, Huilan Liu, Weili Zhao, Ru Feng, Wenqi Jiang, Hong Cen, Fangfang Lv, Yunhong Huang, Ding Yu, Qunyi Guo, Lie Lin, Jianzhen Shen, Donghua Zhang, Jishi Wang, Xiongpeng Zhu, Meizuo Zhong, Jingbo Wang, Zhao Wang, Hongguo Zhao
Format: Article
Language:English
Published: BMJ Publishing Group 2024-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/10/e008895.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/10/e008895.full

Similar Items